Abbott Laboratories vs GE HealthCare
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Abbott Laboratories and GE HealthCare side by side, using each one’s latest annual report. Here is what stands out:
- Abbott Laboratories is the larger business, with $44.3B of revenue in fiscal 2025 against $20.6B for GE HealthCare, about 2.1 times as much.
- Abbott Laboratories grew revenue faster (5.7%, against 4.8%).
- Abbott Laboratories kept more of each dollar of sales as operating profit (18.2% operating margin, against 13.4%).
- Abbott Laboratories turned more of its sales into free cash flow (16.7% FCF margin, against 7.3%).
- GE HealthCare earned a higher return on the capital invested in it (13.3%, against 11.2%).
- Investors pay more for each dollar of Abbott Laboratories’s earnings: a P/E of 29.3x against 17.2x for GE HealthCare.
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
Abbott Laboratories
ABT
6/10
Revenue growthGross marginOperating marginNet marginFCF marginNet debt / EBITDA
GE HealthCare
GEHC
4/10
Return on capitalReturn on equityPiotroski F-scoreShare count change
Side by side
Best in the row
| Latest fiscal year | ABT FY25 | GEHC FY25 |
|---|---|---|
| Size | ||
| Market cap | $183.2B | $32.9B |
| Revenue | $44.3B | $20.6B |
| Free cash flow | $7.4B | $1.5B |
| Net income | $6.5B | $2.1B |
| Growth | ||
| Revenue growth | 5.7% | 4.8% |
| 5-year growth | 5.1% | — |
| Share count change | 0.0% | −0.2% |
| Profitability | ||
| Gross margin | 56.4% | 40.0% |
| Operating margin | 18.2% | 13.4% |
| Net margin | 14.7% | 10.1% |
| FCF margin | 16.7% | 7.3% |
| Return on capital | 11.2% | 13.3% |
| Return on equity | 13.1% | 22.1% |
| Balance sheet | ||
| Net debt | $4.0B | $6.0B |
| Net debt / EBITDA | 0.4x | 1.8x |
| Dividends and buybacks | $5.0B | $264M |
| Valuation & quality | ||
| P/E | 29.3x | 17.2x |
| Piotroski F-score | 6 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.